key: cord-1055827-a6u87kfc
authors: KAHRAMAN, Fatih; ÖZKARA, Adem
title: COVID-19 transmission sources, management, and scientific research in Turkey
date: 2021-04-30
journal: Turk J Med Sci
DOI: 10.3906/sag-2009-159
sha: 4b693520129a5a937c2f21bff273c2e64f064e76
doc_id: 1055827
cord_uid: a6u87kfc

Letter to the Editor.

phylogenetically analyzed in Turkish laboratories and in laboratories around the world, and the results were documented in the global initiative on sharing all influenza data (GISAID) platform 2 . Karacan et al. analyzed the viral isolates of three COVID-19-positive patients and found that all three isolates carried the D614G variant in the S gene, indicating that they are all in the G clade, which was mostly detected in European countries [2] . In addition, Adebali et al. performed a phylogenetic analysis of the first thirty SARS-CoV-2 genomes isolated and sequenced in Turkey [3] . Their analysis suggested multiple independent international introductions of the virus to the country. They clustered the genomes based on their clade distribution in the phylogenetic tree and found that most samples from Turkey belong to cluster four, which is also prevalent in Iran, Denmark, and France. They found a connection to Saudi Arabia in only two cities in Turkey, while the Europe-based introductions were identified in the genomes isolated from İstanbul, the epicenter of Turkey's COVID-19 outbreak. In addition, according to Turkish Ministry of Culture and Tourism data on border introduction counts between January and March, Iran and Saudi Arabia accounted for only 6.72% of all visitors (5.19% from Iran and 1.53% from Saudi Arabia). During the same interval, entry from Europe constituted 38.52% of all visitors (24.88% from OECD countries and 13.79% from non-OECD countries) 3 . The first COVID-19positive cases were seen within the same day in Iran and Europe, nearly 20 days before Turkey's first documented case. Furthermore, Turkey closed its border with Iran on February 23 after Iran's first cases of COVID-19 were confirmed on February 19; however, flights to and from Italy, one of the European countries most affected by COVID-19, were not cancelled until February 29. Additionally, Turkish visitors returning from pilgrimages in Saudi Arabia were checked with thermal cameras before boarding and were quarantined in select isolated hostels for 14 days. Considering all this well-documented information, attributing virus introduction to only one or two sources seems illogical.

The authors' next point, that there is a lack of transparency at the Turkish MoH, has already been addressed by the organization in its daily briefings on the MoH website and on social media 4 . The authors' most controversial subject is the alleged restrictions on COVID-19 research. The rumours about research restrictions are simply not true. In fact, the timely responses of the Turkish MoH to research applications encouraged researchers to work faster and more efficiently. According to data from the official MoH website, nearly 5000 research applications regarding COVID-19 were submitted online, and the MoH approved more than 96% of them within five days, allowing researchers to proceed with their proposed studies 5 . Local institutes and councils also supported many trials concerning COVID-19 [2, 3] .

Finally, in addition to this objective data, Turkey's official agencies, healthcare workers, and community have come together to quell the COVID-19 outbreak as successfully as any other country. Personal protective equipment (PPE) was produced in collaboration with formal and private agencies and distributed all around the country. Moreover, Turkey has supported many countries, including the United States and the United Kingdom, with PPE. Two large emergency hospitals were built in İstanbul and began providing services in only 45 days. In addition, mechanical ventilators were produced with 100% local resources for the first time and delivered to local hospitals. With mass production, Turkey was able to manufacture enough ventilators to export to other countries. As a result of these proactive and effective steps, Turkey has had lower mortality rates than many developed countries (Table) .

We have no conflicts of interest to disclose related to this letter. 

Interference in scientific research on COVID-19 in Turkey

The origin of SARS-CoV-2 in İstanbul: sequencing findings from the epicenter of the pandemic in Turkey

Phylogenetic Analysis or SARS-CoV-2 genomes in Turkey